Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PTPRO |
| Gene Name: | PTPRO |
| Protein Full Name: | Receptor-type tyrosine-protein phosphatase O |
| Alias: | Glomerular epithelial protein 1;Protein tyrosine phosphatase U2 |
| Mass (Da): | 138344 |
| Number AA: | 1216 |
| UniProt ID: | Q16827 |
| Locus ID: | 5800 |
| COSMIC ID: | PTPRO |
| Gene location on chromosome: | 12p12.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBIT |
| Number of cancer specimens: | 19810 |
| Percent of cancer specimens with mutations: | 1.14 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | PTPRO is a protein tyrosine phosphatase that plays a role in regulating glomerular pressure/filtration rate. It may also regulate osteoclast production and activity, inhibition of cell proliferation and facilitation of apoptosis and therefore may be regarded as a tumour suppressor. Overexpression inhibited anchorage-independent growth, delayed cell cycle progression and increased susceptibility to apoptosis. Decreased expression has been observed in several cancers. |